.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Express Scripts
Dow
Merck
Julphar
Covington
AstraZeneca
Healthtrust
Deloitte

Generated: December 14, 2017

DrugPatentWatch Database Preview

Aegerion Company Profile

« Back to Dashboard

What is the competitive landscape for AEGERION, and when can generic versions of AEGERION drugs launch?

AEGERION has one approved drug.

There are seven US patents protecting AEGERION drugs.

There are eighty-eight patent family members on AEGERION drugs in thirty-six countries and thirteen supplementary protection certificates in eleven countries.

Summary for Aegerion

International Patents:88
US Patents:7
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-002Dec 21, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-002Dec 21, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-002Dec 21, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-006Apr 23, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-002Dec 21, 2012RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-003Dec 21, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-005Apr 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Aegerion

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-003Dec 21, 2012► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-001Dec 21, 2012► Subscribe► Subscribe
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-002Dec 21, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Aegerion

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,595,872 Nucleic acids encoding microsomal trigyceride transfer protein► Subscribe
6,066,650 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
5,883,099 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
6,034,098 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
5,789,197 Microsomal triglyceride transfer protein► Subscribe
5,739,135 Inhibitors of microsomal triglyceride transfer protein and method► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Aegerion Drugs

Country Document Number Estimated Expiration
LithuaniaC1725234► Subscribe
Canada2091102► Subscribe
Canada2558766► Subscribe
Norway973821► Subscribe
China1106003► Subscribe
CroatiaP20130115► Subscribe
China1108301► Subscribe
Cyprus1114218► Subscribe
European Patent Office0886637► Subscribe
Poland322003► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Aegerion Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
8Finland► Subscribe
13/063Ireland► SubscribePRODUCT NAME: LOMITAPIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
2014001Lithuania► SubscribePRODUCT NAME: LOMITAPIDUM; REGISTRATION NO/DATE: EU/1/13/851/001, 2013 07 31 EU/1/13/851/002, 2013 07 31 EU/1/13/851/003 20130731
0140001 00107Estonia► SubscribePRODUCT NAME: LOMITAPIID;REG NO/DATE: K(2013)5153(LOPLIK) 05.08.2013
6 5001-2014Slovakia► SubscribePRODUCT NAME: LOMITAPID; REGISTRATION NO/DATE: EU/1/13/851/001 - EU/1/13/851/003 20130805
349Luxembourg► SubscribePRODUCT NAME: LOMITAPIDE ET TOUTES SES FORMES THERAPEUTIQUEMENT EQUIVALENTES TELLES QUE PROTEGEES PAR LE BREVET DE BASE. FIRST REGISTRATION: 20130805
C0003France► SubscribePRODUCT NAME: LOMITAPIDE , OU UN SEL PHARMACEUTIQUEMENT ACTIF DE CELUI-CI.; REGISTRATION NO/DATE: EU/1/13/851/001 20130731
90006-2Sweden► SubscribePRODUCT NAME: LOMITAPID OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/13/851/001 20130731
0634Netherlands► SubscribePRODUCT NAME: LOMITAPIDE OF HET PIPERIDINE N-OXIDE DAARVAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130805
00634Netherlands► SubscribePRODUCT NAME: LOMITAPIDE EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN, ZOALS DOOR HET BASISOCTROOI BESCHERMD; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Harvard Business School
Express Scripts
UBS
Baxter
Deloitte
Dow
AstraZeneca
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot